Effect of topical tranexamic acid in the treatment of epistaxis

Phase 2

Recruiting

• Conditions: Epistaxis; R04.0; Haemorrhage from nose, Nosebleed.

• Registration Number: IRCT20221230056992N1
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 106

Inclusion Criteria

patients with acute spontaneous epistaxis
age more than 18
epistaxis is controlled with primary conservative management
patient has a consent to enroll the study

Exclusion Criteria

sensitivity to tranexamic acid
no consent to enroll the study
there is any malignancy in the nasopharynx, nasal cavity or sinonasal tract
prior packing in nasal cavities when come to ER
pregnancy or breastfeeding
history of coagulopathies
hemodynamic instability
second stage of hypertension (SBP>=160 and DBP>=100)
epistaxis following trauma
history of recent myocardial infarction or stroke
renal dysfunction
history of thromboembolism or seizure

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of patients without recurrent epistaxis during 7 days. Timepoint: first day, days 3 and 7 after intervention. Method of measurement: participants statement.

Secondary Outcome Measures

Name	Time	Method
Time to control bleeding. Timepoint: minutes to hours after intervention. Method of measurement: physical examination.;Occurrence of side effects during 7 days. Timepoint: 7 days after intervention. Method of measurement: patient statement.